Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABLE: Glioblastoma Accelerated Biomarkers Learning Environment Trial
NCT06319027Phase 2Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Apr 2024
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoints: Overall Survival up to 6 years and Event Free Survival up to 6 years. Started Apr 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06319027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319027.